Trends in Prevalence, Incidence and Pharmacologic Management of Diabetes Mellitus Among Seniors Newly Admitted to Long-Term Care Facilities in Saskatchewan between 2003 and 2011

Canadian Journal of Diabetes

Volumn 39, Issue 2, 2015, Pages 138-145

  Alsabbagh, Mhd Wasem ^a   Mansell, Kerry ^a   Lix, Lisa M ^b   Teare, Gary ^c   Shevchuk, Yvonne ^a   Lu, Xinya ^c   Champagne, Anne ^d   Blackburn, David F ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c Saskatchewan Health   (Canada)

^d Government of Saskatchewan   (Canada)

Author keywords

Antihyperglycemic agents; Elderly; Long term care; Longitudinal trend

Indexed keywords

ACARBOSE; GLIBENCLAMIDE; GLITAZONE DERIVATIVE; INSULIN; ISOPHANE INSULIN; MEGLITINIDE; METFORMIN; ORAL ANTIDIABETIC AGENT; PIG INSULIN; SULFONYLUREA DERIVATIVE; ANTIDIABETIC AGENT;

AGED; ARTICLE; CHEMOTHERAPY; CLINICAL PRACTICE; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC PATIENT; DRUG SAFETY; DRUG USE; FEMALE; HEALTH CARE FACILITY; HUMAN; INCIDENCE; INSULIN TREATMENT; LONG TERM CARE FACILITY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NURSING HOME PATIENT; PATIENT CARE; PATIENT IDENTIFICATION; PRESCRIPTION; PREVALENCE; RETROSPECTIVE STUDY; SELF REPORT; TREND STUDY; VALIDATION PROCESS; VERY ELDERLY; CANADA; HOME FOR THE AGED; LONG TERM CARE;

AGED; AGED, 80 AND OVER; DIABETES MELLITUS; FEMALE; GLYBURIDE; HOMES FOR THE AGED; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; INSULIN; LONG-TERM CARE; MALE; METFORMIN; PREVALENCE; RETROSPECTIVE STUDIES; SASKATCHEWAN;

EID: 84925046440     PISSN: 14992671     EISSN: 23523840     Source Type: Journal    
DOI: 10.1016/j.jcjd.2014.10.002     Document Type: Article

References (20)

1. Public Health Agency of Canada. Diabetes in Canada: Facts and figures from a public health perspective. Updated 2012. Accessed December 12, 2012. http://www.phac-aspc.gc.ca/cd-mc/publications/diabetes-diabete/facts-figures-faits-chiffres-2011/index-eng.php.
2. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee Canadian Diabetes Association 2013 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2013, 37(Suppl 1):1-212.
3. American Geriatrics Society 2012 Beers Criteria Update Expert Panel American Geriatrics Society updated Beers criteria for potentially inappropriate medication use in older adults. JAm Geriatr Soc 2012, 60:616-631.
4. Shorr R.I., Franse L.V., Resnick H.E., et al. Glycemic control of older adults with type2 diabetes: Findings from the third National Health and Nutrition Examination Survey, 1988-1994. JAm Geriatr Soc 2000, 48:264-267.
5. Van Staa T., Abenhaim L., Monette J. Rates of hypoglycemia in users of sulfonylureas. JClin Epidemiol 1997, 50:735-741.
6. Laubscher T., Regier L., Bareham J. Diabetes in the frail elderly: Individualization of glycemic management. Can Fam Physician 2012, 58:543-546.
7. Shorr R.I., Ray W.A., Daugherty J.R., Griffin M.R. Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas. Arch Intern Med 1997, 157:1681-1686.
8. Lix L.M., Yan L., Blackburn D., et al. Validity of the RAI-MDS for ascertaining diabetes and comorbid conditions in long-term care facility residents. BMC Health Serv Res 2014, 14:17.
9. Clement M., Leung F. Diabetes and the frail elderly in long-term care. Can J Diabetes 2009, 33:114-121.
10. Garcia T.J., Brown S.A. Diabetes management in the nursing home: A systematic review of the literature. Diabetes Educ 2011, 37:167-187.
11. Stergachis A., Saunders K.W., David R.L., et al. Chapter 12: Examples of automated databases. Textbook of Pharmacoepidemiology 2006, Wiley, New York. 5th edn. B.L. Strom, S.E. Kimmel (Eds.).
12. Edouard L., Rawson N.S. Reliability of the recording of hysterectomy in the Saskatchewan health care system. Br J Obstet Gynaecol 1996, 103:891-897.
13. Liu L., Reeder B., Shuaib A., Mazagri R. Validity of stroke diagnosis on hospital discharge records in Saskatchewan, Canada: Implications for stroke surveillance. Cerebrovasc Dis 1999, 9:224-230.
14. Rawson N.S., Malcolm E. Validity of the recording of ischaemic heart disease and chronic obstructive pulmonary disease in the Saskatchewan health care datafiles. Stat Med 1995, 14:2627-2643.
15. Koleba T., Pohar S.L., Johnson J.A. Prescription drug data and the national diabetes surveillance system case definition. Can J Diabetes 2007, 31:47-53.
16. Borah B.J., Darkow T., Bouchard J., et al. Acomparison of insulin use, glycemic control, and health care costs with insulin detemir and insulin glargine in insulin-naive patients with type 2 diabetes. Clin Ther 2009, 31:623-631.
17. McAdam-Marx C., Yu J., Bouchard J., et al. Comparison of daily insulin dose and other antidiabetic medications usage for type 2 diabetes patients treated with an analog basal insulin. Curr Med Res Opin 2010, 26:191-201.
18. Meneilly G.S., Tessier D. Diabetes in elderly adults. JGerontol A Biol Sci Med Sci 2001, 56:M5-M13.
19. Lecka-Czernik B. Bone loss in diabetes: Use of antidiabetic thiazolidinediones and secondary osteoporosis. Curr Osteoporos Rep 2010, 8:178-184.
20. Morrow R.L., Carney G., Wright J.M., et al. Impact of rosiglitazone meta-analysis on use of glucose-lowering medications. Open Med 2010, 4:e50-e59.